Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Lymphoma

This is the study of the PI3K inhibitor Zandelisib (ME-401) in subjects with
relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2
prior lines of systemic therapy
Lymphoma
II
Dholaria, Bhagirathbhai
NCT03768505
VICCPCL1913

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: